This “synthetic lethality” effect of PARP‐1 inhibition is effective in breast cancer with BRCA mutations, but not in breast cancer with wild‐type BRCA [9, 10] and is enlarged to cover cancer cells showing other HR protein deficiencies [11]. The gene discussed is PARP1; the disease is cancer.